Have a feature idea you'd love to see implemented?
Let us know!
ANVS Annovis Bio Inc
Price (delayed)
$6.79
Market cap
$93.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.84
Enterprise value
$81.05M
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS).
Highlights
The quick ratio has soared by 136% since the previous quarter and by 31% year-on-year
The EPS has grown by 20% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of ANVS
Market
Valuations
Earnings
Shares outstanding
13.8M
Market cap
$93.68M
Enterprise value
$81.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
12.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$40.94M
EBITDA
-$40.94M
Free cash flow
-$22.97M
Per share
Balance sheet
Liquidity
EPS
-$3.84
Free cash flow per share
-$1.77
Book value per share
$0.54
Revenue per share
$0
TBVPS
$1.11
Total assets
$14.36M
Total liabilities
$7.3M
Debt
$0
Equity
$7.06M
Working capital
$8.97M
Debt to equity
0
Current ratio
2.66
Quick ratio
2.34
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-437.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-456.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANVS stock price
How has the Annovis Bio stock price performed over time
Intraday
3.82%
1 week
-2.58%
1 month
-30.86%
1 year
2.88%
YTD
-63.69%
QTD
-15.76%
Financial performance
How have Annovis Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.4M
Net income
-$40.94M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 28% YoY and by 26% QoQ
The net income is up by 4.8% since the previous quarter
Growth
What is Annovis Bio's growth rate over time
Valuation
What is Annovis Bio stock price valuation
P/E
N/A
P/B
12.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 20% year-on-year and by 15% since the previous quarter
The price to book (P/B) is 44% more than the 5-year quarterly average of 8.4
ANVS's equity is up by 6% year-on-year
Efficiency
How efficient is Annovis Bio business performance
The return on assets has dropped by 148% year-on-year but it is up by 15% since the previous quarter
Dividends
What is ANVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANVS.
Financial health
How did Annovis Bio financials performed over time
Annovis Bio's total assets is 97% higher than its total liabilities
Annovis Bio's total assets has surged by 185% QoQ and by 40% YoY
The quick ratio has soared by 136% since the previous quarter and by 31% year-on-year
The company's debt is 100% lower than its equity
ANVS's equity is up by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.